Valuation: PolyPeptide Group AG

Market Cap 1.57B 1.76B 1.46B 1.33B 2.5B 167B 2.52B 17.52B 6.86B 86.72B 6.6B 6.45B 278B P/E 2026 *
58.5x
P/E 2027 * 31.1x
Enterprise Value 1.67B 1.87B 1.56B 1.41B 2.66B 177B 2.68B 18.65B 7.3B 92.3B 7.02B 6.87B 296B EV / Sales 2026 *
3.33x
EV / Sales 2027 * 2.95x
Free-Float
39.12%
Yield 2026 *
-
Yield 2027 * 0.14%
1 week 44
Extreme 44
44.15
1 month 44
Extreme 44
44.15
Current year 44
Extreme 44
44.15
1 year 44
Extreme 44
44.15
3 years 44
Extreme 44
44.15
5 years 44
Extreme 44
44.15
10 years 44
Extreme 44
44.15
Manager TitleAgeSince
Chief Executive Officer 54 11/04/2023
Director of Finance/CFO 54 01/01/2024
Chief Tech/Sci/R&D Officer 54 -
Director TitleAgeSince
Director/Board Member 73 31/12/2005
Chairman 69 31/03/2021
Director/Board Member 62 31/12/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.34%-0.11% - - 1.74B
-1.36%+0.78%+42.36%+91.48% 1,054B
-5.73%-2.42%+30.23%+58.50% 636B
-2.40%+2.88%+19.13%+85.43% 497B
-2.39%+0.03%+65.67%+36.51% 359B
-0.06%+2.86%+24.03%+41.07% 345B
-0.55%+1.81%+14.16%+36.31% 273B
-1.08%-0.52%-6.51%+8.40% 246B
-1.13%+2.54%+41.19%+45.32% 226B
-1.67%+2.56%+25.13%+90.50% 187B
Average -1.39%+2.55%+28.38%+54.83% 424.69B
Weighted average by Cap. -1.36%+2.44%+31.78%+63.43%

Financials

2026 *2027 *
Net sales 502M 562M 468M 424M 798M 53.33B 804M 5.6B 2.19B 27.74B 2.11B 2.06B 89.01B 576M 645M 537M 487M 916M 61.21B 923M 6.43B 2.52B 31.83B 2.42B 2.37B 102B
Net income 23.5M 26.31M 21.91M 19.86M 37.38M 2.5B 37.67M 262M 103M 1.3B 98.82M 96.65M 4.17B 45.23M 50.63M 42.16M 38.22M 71.93M 4.81B 72.49M 505M 198M 2.5B 190M 186M 8.02B
Net Debt 101M 113M 94.1M 85.31M 161M 10.73B 162M 1.13B 441M 5.58B 424M 415M 17.9B 131M 147M 122M 111M 208M 13.91B 210M 1.46B 572M 7.23B 550M 538M 23.21B
Projected Income Statement - Annual - PolyPeptide Group AG
Logo PolyPeptide Group AG
Polypeptide Group AG is a Switzerland-based Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products.
Employees
1,460
Date Price Change
13/10/26 CHF 44.00 -0.34%
12/10/26 CHF 44.15 +0.23%
09/10/26 CHF 44.05 0.00%
08/10/26 CHF 44.05 0.00%
07/10/26 CHF 44.05 0.00%
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - PolyPeptide Group AG
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
47.53EUR
Average target price
45.99EUR
Spread / Average Target
-3.24%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - PolyPeptide Group AG